Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Receivables - Other (2019 - 2025)

Corcept Therapeutics (CORT) has disclosed Receivables - Other for 7 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For Q4 2025, Receivables - Other changed 0.0% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, changed 0.0%, while the annual FY2025 figure was $4.1 million, N/A changed from the prior year.
  • Receivables - Other hit $4.1 million in Q4 2025 for Corcept Therapeutics, up from $3.9 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $18.2 million in Q1 2025 and bottomed at $900000.0 in Q3 2022.
  • Average Receivables - Other over 5 years is $5.8 million, with a median of $3.4 million recorded in 2024.
  • On a YoY basis, Receivables - Other climbed as much as 1455.56% in 2023 and fell as far as 87.86% in 2023.
  • Corcept Therapeutics' Receivables - Other stood at $1.4 million in 2021, then skyrocketed by 900.0% to $14.0 million in 2022, then crashed by 87.86% to $1.7 million in 2023, then soared by 141.18% to $4.1 million in 2024, then decreased by 0.0% to $4.1 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $4.1 million, $3.9 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.